Cerebrolysin

Cerebrolysin is a porcine brain derived preparation of low molecular weight peptides (under 10 kDa) and free amino acids, approximately 75 to 85% amino acids and 15 to 25% neuropeptides, comprising over 100 distinct oligopeptides. It is a complex biological rather than a defined single molecule, which shapes everything about its pharmacology and its sourcing.

The peptide fragments mimic endogenous neurotrophic factors, interacting with pathways associated with BDNF, NGF, GDNF and CNTF without binding a single dedicated receptor. Earlier product descriptions also attributed activity to P21 (neurogenesis and plasticity), enkephalins (opioid receptor mediated pain and stress regulation) and orexin (sleep, appetite, metabolism and arousal); the enkephalin content is the plausible basis for the MAOI and antidepressant cautions in the contraindications.

The sub 10 kDa fragment size permits blood brain barrier passage, which full length BDNF and NGF cannot achieve peripherally.

Developed in Austria in 1949 by EVER Pharma, it is approved in over 45 countries across Europe, Asia and Latin America for stroke recovery, traumatic brain injury, dementia and Alzheimer's disease. It is not FDA approved.

Cerebrolysin (EVER Pharma) and generic cerebroprotein hydrolysate are not interchangeable. Windisch and colleagues (International Journal of Molecular Sciences, 2024) found significant differences in peptide composition and biological activity between preparations; Cerebrolysin was the only one inducing relevant neurofilament expression. Research supplier products labelled Cerebrolysin are cerebroprotein hydrolysate, and users report less consistent responses from them. Batch composition in any tissue derived complex is inherently less defined than in a synthetic peptide.

Route is intramuscular (deltoid or gluteal) at 1 to 5 mL per administration, with prescribing guidelines capping single IM doses at 5 mL. Clinical IV infusion protocols of 10 to 60 mL daily exist but are hospital based and physician supervised.

Cerebrolysin acts through a coordinated set of mechanisms rather than a single pathway, reflecting its content of over 100 oligopeptides.

Neurotrophic factor mimicry. The fragments engage pathways associated with BDNF, NGF, GDNF and CNTF without a single dedicated receptor. Aleixandre and colleagues (International Journal of Neuropsychopharmacology, 2016) reported a 300% increase in serum BDNF over 16 weeks in Alzheimer's patients on Cerebrolysin alone and 600% in combination with donepezil. This contrasts with Semax, which upregulates BDNF via central gene expression changes; the two reach overlapping downstream effects from different directions.

Neuroprotection. Reduction of glutamate excitotoxicity, inhibition of free radical formation and oxidative stress, suppression of pathological microglial activation, inhibition of apoptosis and protection against lactic acidosis. The profile is most relevant in the acute post-stroke and post-TBI settings and in progressive neurodegeneration.

Neuroplasticity. Increased synaptogenesis, dendritic branching and spine density, axonal sprouting and enhanced synaptic plasticity; this is the substrate for the learning and memory effects.

Neurogenesis. Proliferation, differentiation and migration of neural progenitor cells.

Signalling modulation. Effects on the sonic hedgehog (Shh) pathway, regulating neurogenesis, angiogenesis, myelination and neurovascular unit maintenance.

Amyloid beta. In Alzheimer's models, reduced amyloid beta production via altered amyloid precursor protein processing and possible reduction of existing deposits. Human evidence for this specific effect is limited.

Earlier component-level descriptions add enkephalin mediated opioid receptor activity (pain and stress regulation) and orexin mediated arousal, sleep and metabolic effects, which account for some of the tolerability profile (agitation, sweating) and the monoaminergic interaction cautions.

Stroke. The most studied and most contested indication. CASTA (over 1,000 patients) failed to show benefit for composite outcomes with acute stand-alone use. Ziganshina and colleagues (Cochrane, 2020) concluded Cerebrolysin probably does not reduce death in acute ischaemic stroke and may increase non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23). Against that, Bornstein and colleagues (Neurological Sciences, 2018; nine RCTs, 1,879 patients) found superiority over placebo on day 30 NIHSS, and Chang and colleagues (BMC Neurology, 2016) found better motor recovery with Cerebrolysin plus standardised rehabilitation than rehabilitation alone in severe motor impairment. A 2025 observational study reported NIHSS falling from 9.90 to 3.40 versus 10.10 to 4.80 with standard therapy. CLINCH (88 patients, 50 mL daily for 14 days, intracerebral haemorrhage) is pending. Net: adjunct to rehabilitation, not acute monotherapy. Mild post-stroke fever is a recognised effect and warrants medical evaluation.

TBI. CAPTAIN II (Muresanu and colleagues, Neurological Sciences, 2020) showed improved neurorecovery in moderate to severe TBI; one of the more consistent indications.

Alzheimer's. Gauthier and colleagues (2015; six RCTs) found significant cognitive benefit at 4 weeks (SMD -0.40; p = 0.0031), maintained up to 6 months after treatment, with safety comparable to placebo. A 24 week dose ranging study (10, 30 and 60 mL) showed dose dependent benefit. Synergistic BDNF elevation with donepezil (600% versus 300%).

Vascular dementia. Chen and colleagues (Cochrane, 2013; six RCTs, 597 participants) found benefit on MMSE and ADAS-cog.

Other. Parkinson's disease (dopaminergic protection via GDNF pathway effects), peripheral neuropathy, multiple sclerosis, chronic migraine prevention (no mechanism offered), ADHD (70 to 86% improvement in one study), treatment-resistant depression as an antidepressant adjunct, and infant cerebral palsy after perinatal brain insult.

Evidence quality varies and some studies carry manufacturer ties.

Onset is gradual. Effects build over days to weeks of daily administration and the standard course runs 20 to 40 days, in contrast to Semax's acute onset within 20 minutes.

Weeks 1 to 2. Subtle gains in clarity, focus and information uptake in some users; no perceptible change in others. Structural neurotrophic effects lag behind administration.

Weeks 2 to 4. The window in which cognitive benefit becomes consistent. Users report improved memory, verbal fluency and processing; clinical trials record measurable gains on standardised testing here.

Post-course persistence. Benefit commonly persists for weeks to months after cessation. Alzheimer's data show improvements maintained up to 6 months after a 4 week course, consistent with durable synaptic and structural change rather than a transient pharmacodynamic effect.

Response is strongest in users with a defined insult: concussion, TBI, neurotoxic exposure or a diagnosed neurological condition. Healthy users seeking optimisation report more modest effects, and the risk-benefit profile in that population is less studied.

Administration. IM volumes of up to 5 mL produce injection site soreness, transient flushing and warmth. Slow injection over 3 to 5 minutes reduces this; cold compresses are used post-injection in practice.

Source dependence. Users report more consistent effects from EVER Pharma Cerebrolysin than from generic cerebroprotein hydrolysate, consistent with Windisch and colleagues (2024).

Route. Intramuscular, deltoid or gluteal, injected over 3 to 5 minutes. Prescribing guidelines cap a single IM dose at 5 mL. Subcutaneous use is practised for convenience but is less documented; 1 to 2 mL is the practical ceiling for that route.

IM protocol, cognitive support. 1 to 2 mL once daily for 20 to 40 days, followed by 60 to 80 days off.

IM protocol, neuroprotection. 2 to 5 mL once daily for 20 to 30 days, followed by 60 to 80 days off.

Start at the lower end to assess tolerance. Timing is unconstrained; morning or early afternoon is typical and fasting is not required.

Clinical IV reference. Dementia 5 to 30 mL daily in 4 week courses; acute stroke 10 to 50 mL daily for 10 to 21 days; TBI 10 to 60 mL daily in the acute phase; infusion over 15 to 60 minutes minimum. Physician supervised, hospital based, not appropriate for home use.

Concentration caveat. The mL figures describe pharmaceutical Cerebrolysin, which is supplied as a fixed-concentration solution. Research-grade cerebroprotein hydrolysate is a lyophilised vial whose concentration depends on the diluent volume, so mL figures do not transfer directly. The earlier protocol for the 64 mg research vial (derived from 100 units = 8 mg = 1 mL) reconstituted with 8 mL (800 units) of bacteriostatic water to 8 mg/mL and escalated by frequency rather than dose: 100 units once daily in week 1 (8 mg), twice daily in week 2 (16 mg total), three times daily in weeks 3 to 4 (24 mg total), over a 4 week cycle with a 2 to 4 week washout. The listed research product is 60 mg. The protocol rows below use the 8 mg/mL figure to convert volume to mass; adjust for actual concentration.

Storage. Refrigerated, do not freeze, stated shelf life up to 5 years; no distinction is made between reconstituted and unreconstituted.

Effects take days to weeks; benefits may persist for weeks to months after cessation. Cycling with rest periods is intended to prevent adaptation.

The evidence base is extensive but heterogeneous, with much of it from European and Asian investigators and some manufacturer involvement.

Alzheimer's disease (most consistent). Gauthier et al. (2015), a meta-analysis of six RCTs, found Cerebrolysin significantly superior to placebo on cognitive function at 4 weeks (SMD -0.40; p = 0.0031), with safety comparable to placebo and benefits maintained up to 6 months post-treatment. Multiple 4 week courses at 30 mL daily IV improved standardised cognitive scores. A 24 week double-blind placebo-controlled dose-ranging study (10 mL, 30 mL, 60 mL) showed benefit at all doses with a dose-response gradient. Aleixandre et al. (2016) reported serum BDNF increased by 300% over 16 weeks with Cerebrolysin alone and 600% when combined with donepezil.

Vascular dementia (moderate). Chen et al. (2013), Cochrane, six RCTs, 597 participants: beneficial effects on MMSE or ADAS-cog and global function; more high-quality research requested.

Traumatic brain injury (promising). CAPTAIN II (Muresanu et al., 2020) showed improved neurorecovery outcomes in moderate to severe TBI.

Stroke (mixed). CASTA (Guekht et al., 2011), over 1,000 patients, failed to show benefit on composite outcomes for acute monotherapy. Ziganshina et al. (2020), Cochrane, concluded Cerebrolysin probably has no effect on mortality in acute ischaemic stroke and may increase non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23). Against that, Bornstein et al. (2018), nine RCTs, 1,879 patients, found superiority on NIHSS at day 30; Chang et al. (2016) found Cerebrolysin plus standardised rehabilitation improved motor recovery and corticospinal tract changes versus rehabilitation alone in severe motor impairment. A 2025 observational study reported NIHSS falling from 9.90 to 3.40 with Cerebrolysin plus standard therapy versus 10.10 to 4.80 with standard therapy alone. The CLINCH pilot (88 patients, 50 mL daily for 14 days, intracerebral haemorrhage) is pending.

Safety. Thome and Doppler (2012) and a 2021 meta-analysis of 12 RCTs (2,202 patients) found no significant overall safety difference from placebo; the Cochrane non-fatal SAE signal in acute stroke stands as the exception.

Mechanistic and comparative. Windisch et al. (2024) found Cerebrolysin was the only preparation among those compared able to induce relevant neurofilament expression, distinguishing it from generic cerebroprotein hydrolysate. Rejdak et al. (2023) reviews neurotrophic factor modulation across dementia, stroke, and TBI.

No trial has tested Cerebrolysin as a preventive or enhancement agent in healthy adults; optimisation use extrapolates from patient populations.